ES2331083T3 - Mejora de la calidad de imagen en el ojo. - Google Patents

Mejora de la calidad de imagen en el ojo. Download PDF

Info

Publication number
ES2331083T3
ES2331083T3 ES05759460T ES05759460T ES2331083T3 ES 2331083 T3 ES2331083 T3 ES 2331083T3 ES 05759460 T ES05759460 T ES 05759460T ES 05759460 T ES05759460 T ES 05759460T ES 2331083 T3 ES2331083 T3 ES 2331083T3
Authority
ES
Spain
Prior art keywords
zeaxanthin
lutein
composition
eye
mixtures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05759460T
Other languages
English (en)
Spanish (es)
Inventor
John Barbur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Application granted granted Critical
Publication of ES2331083T3 publication Critical patent/ES2331083T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Eye Examination Apparatus (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
ES05759460T 2004-06-29 2005-06-08 Mejora de la calidad de imagen en el ojo. Expired - Lifetime ES2331083T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04015189 2004-06-29
EP04015189 2004-06-29

Publications (1)

Publication Number Publication Date
ES2331083T3 true ES2331083T3 (es) 2009-12-21

Family

ID=35782481

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05759460T Expired - Lifetime ES2331083T3 (es) 2004-06-29 2005-06-08 Mejora de la calidad de imagen en el ojo.

Country Status (9)

Country Link
US (2) US20080045605A1 (enExample)
EP (1) EP1761254B1 (enExample)
JP (1) JP5074184B2 (enExample)
KR (1) KR20070027649A (enExample)
CN (1) CN101094666B (enExample)
AT (1) ATE441406T1 (enExample)
DE (1) DE602005016405D1 (enExample)
ES (1) ES2331083T3 (enExample)
WO (1) WO2006002735A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084687A1 (en) * 2005-02-11 2006-08-17 Dsm Ip Assets B.V. Use of zeaxanthin for the treatment of diseases of the peripheral retina
AT503329A1 (de) * 2006-03-02 2007-09-15 Omnica Gmbh Verfahren zur herstellung einer zusammensetzung, welche zumindest ein xantophyll enthält

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218436B1 (en) * 1993-06-28 2001-04-17 The Howard Foundation Pharmaceutically active carotenoids
US5382714A (en) * 1994-03-17 1995-01-17 The Catholic University Of America Process for isolation, purification, and recrystallization of lutein from saponified marigold oleoresin and uses thereof
US5827652A (en) * 1995-10-31 1998-10-27 Applied Food Biotechnology, Inc. Zeaxanthin formulations for human ingestion
FR2749758B1 (fr) * 1996-06-12 1998-08-07 Oenobiol Sa Lab Composition a activite bronzante et photoprotectrice et ses applications esthetiques
WO1997048388A1 (en) * 1996-06-17 1997-12-24 The Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
US6075058A (en) * 1998-12-12 2000-06-13 Tufts University Compositions for increased bioavailability of carotenoids
US6712466B2 (en) * 2001-10-25 2004-03-30 Ophthonix, Inc. Eyeglass manufacturing method using variable index layer
ES2299687T3 (es) * 2002-01-30 2008-06-01 Dsm Ip Assets B.V. Luteina/zeaxantina para la proteccion contra el encandilamiento.
CN1481804A (zh) * 2002-12-17 2004-03-17 无锡杰西医药科技有限公司 防治白内障、黄斑变性等眼病的配方及其使用方法

Also Published As

Publication number Publication date
CN101094666A (zh) 2007-12-26
JP2008505137A (ja) 2008-02-21
ATE441406T1 (de) 2009-09-15
EP1761254A1 (en) 2007-03-14
US20080045605A1 (en) 2008-02-21
CN101094666B (zh) 2010-09-29
WO2006002735A1 (en) 2006-01-12
KR20070027649A (ko) 2007-03-09
EP1761254B1 (en) 2009-09-02
DE602005016405D1 (de) 2009-10-15
US20110172313A1 (en) 2011-07-14
JP5074184B2 (ja) 2012-11-14

Similar Documents

Publication Publication Date Title
ES2955713T3 (es) Agente de mejora de la función visual, y método para mejorar la función visual
ES2732744T3 (es) Composición para la salud ocular
US20230321023A1 (en) Application of regulation of eye sclera lipid metabolism to inhibit myopia
CN114796205B (zh) 用于治疗近视的方法和药物组合物
US20130045940A1 (en) Composition comprising as active ingredient l-carnitine in combination with a solar filter, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation
CN102178925A (zh) 新型视力保护剂叶黄素眼用制剂
Kono et al. Effect of multiple dietary supplement containing lutein, astaxanthin, cyanidin-3-glucoside, and DHA on accommodative ability
Spence et al. A brief review of three common supplements used in Alzheimer's disease
ES2292754T3 (es) Atenuacion de un error de funcion de control del ojo.
ES2331083T3 (es) Mejora de la calidad de imagen en el ojo.
JP5848042B2 (ja) 眼疲労抑制組成物及びそれを含む飲食品
ES2993253T3 (en) Composition of a dietary supplement and/or a nutritional additive for food, a unitary dosage form of said composition, and their use for improvement of the quality of visual performance including contrast sensitivity in persons in need of such an improvement, including persons suffering from at least one eye disease, particularly vitreous floaters
US20070082066A1 (en) Use of zeaxanthin to reduce light hyper-sensitivity, photophobia, and medical conditions relating to light hyper-sensitivity
ES2685324B1 (es) Composición farmacéutica o complemento nutricional para la prevención y/o el tratamiento del ojo seco
Arivuchudar et al. An overview on the sway of nutritional supplements on dry eye disease
Bharadwaj et al. Beneficial effects of a lutein-zeaxanthin complex on macular pigment optical density levels of healthy individuals with prolonged screen time
ES2886723A1 (es) Composicion basada en la actividad antioxidante de la enzima superoxido dismutasa y su aplicacion en enfermedades oculares
ES2955318T3 (es) Composición de Desmodium y cromo trivalente y uso ocular
Parker Digital Eye Strain (DES) Supplements: Evidence-Based Guide 2025
Eyres Lipids and nutraceutical news
TWI708602B (zh) 組合物用於製備改善顏色辨識能力或改善色差辨識能力之藥物之用途
Anshel Providing nutritional support for glaucoma management: Supplementing vision care with nutrition may protect ocular tissues.
HK40068445A (en) Composition of a dietary supplement and/or a nutritional additive for food, a unitary dosage form of said composition, and their use for improvement of the quality of visual performance including contrast sensitivity in persons in need of such an improvement, including persons suffering from at least one eye disease, particularly vitreous floaters
Kmiecik et al. The influence of selected active substances on the functioning of the visual system
Jeffrey Anshel Providing nutritional support for glaucoma management